TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02996383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal fixation
Description: Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Hemiarthroplasty
Description: Replacement of the femoral head with a cemented hemiarthroplasty
Study: NCT03933059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.
Study: NCT03447834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective intracoronary hypothermia + PPCI
Description: Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard PPCI
Description: PPCI per routine
Study: NCT04301973

Intervention type: OTHER
Group type: OTHER
Intervention: Stool collection
Description: There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
Study: NCT00926523

Intervention type: OTHER
Intervention: Blood Gas
Description: Subject will have both venous and arterial blood draws to assess for the bloods content of MIF

Intervention type: OTHER
Intervention: Blood Gas
Description: Subject will have both venous and arterial blood draws to assess for the bloods content of MIF

Intervention type: OTHER
Intervention: Pulmonary Exercise Test
Description: Subject will ride exercise bike to assess their pulmonary function level.

Intervention type: OTHER
Intervention: Pulmonary Exercise Test
Description: Subject will ride exercise bike to assess their pulmonary function level.

Intervention type: OTHER
Intervention: Spirometry
Description: To assess subjects lung function

Intervention type: OTHER
Intervention: Spirometry
Description: To assess subjects lung function

Intervention type: OTHER
Intervention: Breath Condensate Collector
Description: Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.

Intervention type: OTHER
Intervention: Breath Condensate Collector
Description: Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
Study: NCT05009355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: antioxidant
Study: NCT04215367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High phenolic EVOO intake
Description: During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No High phenolic EVOO intake
Description: Medical record of each patient's was followed during 6 month before dietary the intervention
Study: NCT03147326

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET-CT
Description: scanning method

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NaF-PET-CT
Description: scanning method

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-body MRI
Description: scanning method
Study: NCT02902926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAPs Diet
Description: Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet instruction
Description: Answer the doubt and help the patient get the diet knowlege about the IBS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet instruction
Description: Answer the doubt and help the patient get the diet knowlege about the IBS.
Study: NCT02016846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04772976

Intervention type: OTHER
Intervention: Observational study, not applicable
Description: Observational study, not applicable

Intervention type: OTHER
Intervention: Observational study, not applicable
Description: Observational study, not applicable
Study: NCT04393727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CONVALESCENT PLASMA
Description: Convalescent plasma will be collected by healthy donors, cured by COVID-19 and, after standard preparation and dosage of neutralizing antibodies, will be administered to patients with SARS-CoV2 pneumonia
Study: NCT01521741

Intervention type: OTHER
Intervention: Breast Cancer-Related Lymphedema Screening
Description: All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.
Study: NCT01712178

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, current formulation
Description: Current formulation adalimumab 40 mg every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab, new formulation
Description: New formulation adalimumab 40 mg every other week
Study: NCT06394258

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Stereotactic body radiotherapy to the vaginal cuff with the aim to reproduce adjuvant high dose rate (HDR) brachytherapy dose distribution by means of external beam radiotherapy in patients operated for intermediate risk endometrial carcinoma
Study: NCT02142842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue stromal vascular fraction and platelet rich plasma
Study: NCT02598674

Intervention type: DRUG
Intervention: Iodohippurate
Description: An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)

Intervention type: PROCEDURE
Intervention: 24 hour ambulatory Blood Pressure
Description: Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.

Intervention type: PROCEDURE
Intervention: 24 hour ambulatory Blood Pressure
Description: Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.

Intervention type: PROCEDURE
Intervention: Peripheral Arterial Tonometry
Description: The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.

Intervention type: PROCEDURE
Intervention: Peripheral Arterial Tonometry
Description: The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.

Intervention type: PROCEDURE
Intervention: Pulse Wave Velocity
Description: Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.

Intervention type: PROCEDURE
Intervention: Pulse Wave Velocity
Description: Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.

Intervention type: DRUG
Intervention: Gadolinium
Description: Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.

Intervention type: DRUG
Intervention: Gadolinium
Description: Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
Study: NCT00880841

Intervention type: DRUG
Intervention: Buprenorphine / Naloxone
Description: oral formulation of buprenorphine / naloxone
Study: NCT02439164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
Study: NCT03277040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSA membership
Description: Bi-weekly fresh food delivery
Study: NCT01979432

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular evaluation
Study: NCT03920956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABPM service by Pharmacists
Description: Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
Study: NCT00651209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
Study: NCT02095288

Intervention type: PROCEDURE
Intervention: Blood draw
Description: This is a single blood donation, no drugs or devices administered
Study: NCT05927662

Intervention type: PROCEDURE
Intervention: lumbar discectomy
Description: mini-open discectomy

Intervention type: PROCEDURE
Intervention: lumbar discectomy
Description: mini-open discectomy
Study: NCT01473004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sir-Spheres®
Description: Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
Study: NCT00657020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine lozenge containing 4 mg of nicotine
Study: NCT02026349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: favipiravir
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.
Study: NCT03594006

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CCI; cancer care coordination instrument
Description: Designed to assess cancer patients' perceptions of care coordination
Study: NCT02415946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation (lateral)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor augmentation (transcrestal)
Study: NCT00827567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD 001
Description: RAD 001-10 mg by mouth once everyday
Study: NCT00748241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech Fixture ST
Description: Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
Study: NCT01102634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Application of TENS over acupuncture points

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Placebo
Study: NCT02054780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Counseling
Description: The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH.
Study: NCT02152007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% sirolimus cream (TD201 1%)
Description: 1% sirolimus cream (TD201 1%)
Study: NCT04638062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.Post Isometric Relaxation
Description: For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.Myofascial Release therapy
Description: For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment.
Study: NCT03451071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil9
Description: Gardasil 9
Study: NCT03727165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous enteral nutrition infusion
Description: Enteral nutrition administration in continuous infusion during 24 hours per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyclic enteral nutrition infusion
Description: Enteral nutrition administration in continuous infusion during 16 hours per day
Study: NCT02667899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Deep brain stimulation means stimulate the brain with DBS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine treatment
Description: Means without above additional treatment.
Study: NCT01741077

Intervention type: DIETARY_SUPPLEMENT
Intervention: folic acid
Description: subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
Study: NCT03764605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day
Study: NCT03689517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: participants took placebos (pills made by starch) that were told to be an effective analgesic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic elastic separators
Description: Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: orthodontic elastic separators
Description: Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
Study: NCT02738502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir monotherapy
Description: darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
Study: NCT03798236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-1650 oral capsules
Description: Adenosine A3 receptor (AA3R) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-1650 oral capsules
Description: Adenosine A3 receptor (AA3R) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-1650 oral capsules
Description: Adenosine A3 receptor (AA3R) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-1650 oral capsules
Description: Adenosine A3 receptor (AA3R) antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: solid microcrystalline cellulose
Study: NCT01855269

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbal drop
Description: Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo sterile water
Study: NCT02737722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphocin Nu-3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04152590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uincare
Description: Interactive digital healthcare system
Study: NCT00379106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm exercises.
Description: Basic active exercise program at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm Exercises
Description: Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
Study: NCT02751229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Honest Open Proud (HOP)
Description: five lessons in three modules, two for each two-hour session~1. Considering pros and cons of disclosing:~   * hurtful and helpful attitudes about mental illness~  * identify beliefs participants hold about themselves~  * explore five-step process to challenge their personally hurtful beliefs~  * weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~2. Different ways to disclose:~   * different levels of (non-) disclosure and how to weigh the cons and pros~  * disclosure via social media versus disclosing face to face~  * how to find people that are better to disclose to than others and how to 'test them out'~  * participants will discuss how others might respond to their disclosure and how that will affect them~3. Telling your story:~   * how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt